Puma Biotechnology Inc (PBYI) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Puma Biotechnology Inc stock (PBYI) is currently trading at $6.26. Puma Biotechnology Inc PE ratio is 10.25. Puma Biotechnology Inc PS ratio (Price-to-Sales) is 1.39. Analyst consensus price target for PBYI is $5.00. WallStSmart rates PBYI as Moderate Buy.
- PBYI PE ratio analysis and historical PE chart
- PBYI PS ratio (Price-to-Sales) history and trend
- PBYI intrinsic value — DCF, Graham Number, EPV models
- PBYI stock price prediction 2025 2026 2027 2028 2029 2030
- PBYI fair value vs current price
- PBYI insider transactions and insider buying
- Is PBYI undervalued or overvalued?
- Puma Biotechnology Inc financial analysis — revenue, earnings, cash flow
- PBYI Piotroski F-Score and Altman Z-Score
- PBYI analyst price target and Smart Rating
Puma Biotechnology Inc
📊 No data available
Try selecting a different time range
PBYI Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Puma Biotechnology Inc (PBYI)
PBYI trades 60% above its Graham fair value of $4.15, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Puma Biotechnology Inc (PBYI) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, operating margin. Concerns around eps growth. Overall metrics suggest strong investment potential with favorable risk/reward.
Puma Biotechnology Inc (PBYI) Key Strengths (6)
Growing significantly faster than its price suggests
Every $100 of shareholder equity generates $28 in profit
72.55% of shares held by major funds and institutions
Strong operational efficiency: $23 kept per $100 revenue
Paying $1.39 for every $1 of annual revenue
Strong revenue growth at 27.70% annually
Supporting Valuation Data
Puma Biotechnology Inc (PBYI) Areas to Watch (4)
Earnings declining -34.40%, profits shrinking
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Decent profitability, keeps $14 per $100 revenue
Supporting Valuation Data
Puma Biotechnology Inc (PBYI) Detailed Analysis Report
Overall Assessment
This company scores 71/100 in our Smart Analysis, earning a B grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 4.3/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on PEG Ratio, Return on Equity, Institutional Own.. Valuation metrics including PEG Ratio (0.03), Price/Sales (1.39) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 28.00%, Operating Margin at 22.70%. Growth metrics are encouraging with Revenue Growth at 27.70%.
The Bear Case
The primary concerns are EPS Growth, Market Cap, Price/Book. Some valuation metrics including Price/Book (2.39) suggest expensive pricing. Growth concerns include EPS Growth at -34.40%, which may limit upside. Profitability pressure is visible in Profit Margin at 13.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 28.00% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 27.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
The combination of PEG Ratio and Return on Equity makes a compelling case at current levels. The key risk is EPS Growth, but the overall fundamental picture is positive with a clear path to maintaining or improving the current B grade.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PBYI Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PBYI's Price-to-Sales ratio of 1.39x trades at a deep discount to its historical average of 8.6x (55th percentile). The current valuation is 99% below its historical high of 124.98x set in Jan 2018, and 209% above its historical low of 0.45x in Feb 2022. Over the past 12 months, the PS ratio has expanded from ~0.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Puma Biotechnology Inc (PBYI) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Puma Biotechnology Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 228M with 28% growth year-over-year. Profit margins of 13.6% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 28% YoY, reaching 228M. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 28.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Margin expansion: can Puma Biotechnology Inc push profit margins above 15% as the business scales?
Growth sustainability: can Puma Biotechnology Inc maintain 28%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Puma Biotechnology Inc.
Bottom Line
Puma Biotechnology Inc offers an attractive blend of growth (28% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(12 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:00:59 AM
About Puma Biotechnology Inc(PBYI)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.